Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
BIOMARKER:
DDR
Associations
(31)
News
Trials
C2 | Sensitive
C3 | Sensitive
D | Sensitive
C2 | Resistant
C3 | Resistant
D | Resistant
Show legend
Include preclinical:
Drug categories
CD Protein Inhibitors
Immune Checkpoint Inhibitors
Immunotherapy
Kinase Inhibitors
Tyrosine Kinase Inhibitors
FGF
PARP Inhibitors
Hormone Therapy
Serine-Threonine Kinase Inhibitors
Cancel
Non Small Cell Lung Cancer
Prostate Cancer
Colorectal Cancer
Breast Cancer
Solid Tumor
Triple Negative Breast Cancer
Melanoma
Pancreatic Cancer
Hepatocellular Cancer
Soft Tissue Sarcoma
Cervical Cancer
Ovarian Cancer
Clear Cell Renal Cell Carcinoma
Cholangiocarcinoma
Urothelial Cancer
Renal Cell Carcinoma
Pancreatic Ductal Adenocarcinoma
Bladder Cancer
olaparib
C3
DDR
|
Prostate Cancer
|
olaparib
C3
DDR
|
Pancreatic Cancer
|
olaparib
C3
DDR
|
Soft Tissue Sarcoma
|
olaparib
C3
DDR
|
Pancreatic Ductal Adenocarcinoma
|
olaparib
Immunotherapy
C3
DDR
|
Non Small Cell Lung Cancer
|
Immunotherapy
C3
DDR
|
Colorectal Cancer
|
Immunotherapy
C3
DDR
|
Breast Cancer
|
Immunotherapy
C3
DDR
|
Melanoma
|
Immunotherapy
C3
DDR
|
Urothelial Cancer
|
Immunotherapy
C3
DDR
|
Bladder Cancer
|
Immunotherapy
PD-L1 inhibitor + CTLA4 inhibitor
C3
DDR
|
Non Small Cell Lung Cancer
|
PD-L1 inhibitor + CTLA4 inhibitor
FOLFOX
C3
DDR
|
Colorectal Cancer
|
FOLFOX
C3
DDR
|
Hepatocellular Cancer
|
FOLFOX
VEGFR inhibitor
C3
DDR
|
Clear Cell Renal Cell Carcinoma
|
VEGFR inhibitor
CAPOX
C3
DDR
|
Colorectal Cancer
|
CAPOX
Tyrosine kinase inhibitor
C3
DDR
|
Renal Cell Carcinoma
|
Tyrosine kinase inhibitor
BAY 1895344
C2
DDR
|
Cervical Cancer
|
BAY 1895344
C3
DDR
|
Ovarian Cancer
|
BAY 1895344
durvalumab
C2
DDR
|
Prostate Cancer
|
durvalumab
atezolizumab
C3
DDR
|
Non Small Cell Lung Cancer
|
atezolizumab
lenvatinib + toripalimab-tpzi
C3
DDR
|
Cholangiocarcinoma
|
lenvatinib + toripalimab-tpzi
pembrolizumab + niraparib
C3
DDR
|
Triple Negative Breast Cancer
|
pembrolizumab + niraparib
nivolumab + ipilimumab
C3
DDR
|
Prostate Cancer
|
nivolumab + ipilimumab
ABT-888
C3
DDR
|
Non Small Cell Lung Cancer
|
ABT-888
talazoparib
C3
DDR
|
Prostate Cancer
|
talazoparib
niraparib
C3
DDR
|
Solid Tumor
|
niraparib
avelumab + talazoparib
C3
DDR
|
Breast Cancer
|
avelumab + talazoparib
sintilimab
C3
DDR
|
Non Small Cell Lung Cancer
|
sintilimab
nivolumab
C3
DDR
|
Solid Tumor
|
nivolumab
abiraterone acetate
C3
DDR
|
Prostate Cancer
|
abiraterone acetate
AZD1390
D
DDR
|
Triple Negative Breast Cancer
|
AZD1390
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
